Rhumbline Advisers raised its holdings in shares of Jazz Pharmaceuticals plc (NASDAQ:JAZZ – Free Report) by 0.8% in the 1st quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 182,475 shares of the specialty pharmaceutical company’s stock after purchasing an additional 1,448 shares during the quarter. Rhumbline Advisers owned approximately 0.29% of Jazz Pharmaceuticals worth $26,702,000 at the end of the most recent reporting period.
Several other hedge funds have also added to or reduced their stakes in the business. Sequoia Financial Advisors LLC lifted its holdings in shares of Jazz Pharmaceuticals by 5.7% during the first quarter. Sequoia Financial Advisors LLC now owns 1,376 shares of the specialty pharmaceutical company’s stock worth $201,000 after buying an additional 74 shares in the last quarter. IFP Advisors Inc increased its position in shares of Jazz Pharmaceuticals by 26.5% in the fourth quarter. IFP Advisors Inc now owns 358 shares of the specialty pharmaceutical company’s stock worth $64,000 after purchasing an additional 75 shares during the period. Captrust Financial Advisors increased its position in shares of Jazz Pharmaceuticals by 2.4% in the first quarter. Captrust Financial Advisors now owns 3,707 shares of the specialty pharmaceutical company’s stock worth $577,000 after purchasing an additional 86 shares during the period. First Republic Investment Management Inc. increased its position in shares of Jazz Pharmaceuticals by 0.7% in the fourth quarter. First Republic Investment Management Inc. now owns 12,062 shares of the specialty pharmaceutical company’s stock worth $1,922,000 after purchasing an additional 88 shares during the period. Finally, Huntington National Bank increased its position in shares of Jazz Pharmaceuticals by 37.9% in the fourth quarter. Huntington National Bank now owns 324 shares of the specialty pharmaceutical company’s stock worth $52,000 after purchasing an additional 89 shares during the period. Institutional investors and hedge funds own 88.15% of the company’s stock.
Insider Buying and Selling at Jazz Pharmaceuticals
In other Jazz Pharmaceuticals news, EVP Neena M. Patil sold 1,600 shares of the business’s stock in a transaction that occurred on Thursday, June 1st. The stock was sold at an average price of $127.98, for a total value of $204,768.00. Following the transaction, the executive vice president now directly owns 32,826 shares of the company’s stock, valued at $4,201,071.48. The sale was disclosed in a legal filing with the SEC, which is available through this link. In other news, Director Rick E. Winningham sold 1,241 shares of the company’s stock in a transaction that occurred on Monday, August 14th. The stock was sold at an average price of $138.16, for a total transaction of $171,456.56. Following the transaction, the director now directly owns 10,444 shares of the company’s stock, valued at $1,442,943.04. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, EVP Neena M. Patil sold 1,600 shares of the company’s stock in a transaction that occurred on Thursday, June 1st. The stock was sold at an average price of $127.98, for a total value of $204,768.00. Following the transaction, the executive vice president now directly owns 32,826 shares in the company, valued at $4,201,071.48. The disclosure for this sale can be found here. Over the last three months, insiders have sold 3,875 shares of company stock valued at $518,864. 4.40% of the stock is currently owned by company insiders.
Analysts Set New Price Targets
Check Out Our Latest Stock Report on Jazz Pharmaceuticals
Jazz Pharmaceuticals Price Performance
Shares of JAZZ opened at $142.10 on Tuesday. Jazz Pharmaceuticals plc has a 52-week low of $120.64 and a 52-week high of $160.96. The company has a debt-to-equity ratio of 1.61, a current ratio of 3.18 and a quick ratio of 2.49. The business’s 50 day moving average price is $130.60 and its two-hundred day moving average price is $135.69.
Jazz Pharmaceuticals Profile
Jazz Pharmaceuticals plc, a biopharmaceutical company, identifies, develops, and commercializes pharmaceutical products for unmet medical needs in the United States, Europe, and internationally. The company has a portfolio of products and product candidates with a focus in the areas of neuroscience, including sleep medicine and movement disorders; and in oncology, such as hematologic and solid tumors.
Featured Articles
- Five stocks we like better than Jazz Pharmaceuticals
- Quiet Period Expirations Explained
- 3 Reasons High-Yield Bloomin’ Brands is About to Blossom
- How to Invest in Grocery Stores
- 5 Computer Vision Stocks with a Clear Path to Growth
- How to Invest in Renewable Energy
- 3 Reasons Workday Stock Is Setting Up For A New Rally
Want to see what other hedge funds are holding JAZZ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Jazz Pharmaceuticals plc (NASDAQ:JAZZ – Free Report).
Receive News & Ratings for Jazz Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Jazz Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
